Theravance Biopharma Inc (NASDAQ: TBPH) kicked off on Monday, up 3.82% from the previous trading day, before settling in for the closing price of $14.66. Over the past 52 weeks, TBPH has traded in a range of $7.90-$15.15.
During the last 5-year period, the sales growth of Healthcare Sector giant was 22.95%. While this was happening, its average annual earnings per share was recorded 230.13%. With a float of $46.73 million, this company’s outstanding shares have now reached $50.36 million.
Theravance Biopharma Inc (TBPH) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Theravance Biopharma Inc is 7.21%, while institutional ownership is 93.69%. The most recent insider transaction that took place on Jul 14 ’25, was worth 113,870. In this transaction SVP, COMM & MEDICAL AFFAIRS of this company sold 10,000 shares at a rate of $11.39, taking the stock ownership to the 326,918 shares. Before that another transaction happened on Jul 14 ’25, when Company’s Officer proposed sale 10,000 for $11.39, making the entire transaction worth $113,869.
Theravance Biopharma Inc (TBPH) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.06 earnings per share (EPS), higher than consensus estimate (set at -0.1) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 230.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 73.26% during the next five years compared to 22.95% growth over the previous five years of trading.
Theravance Biopharma Inc (NASDAQ: TBPH) Trading Performance Indicators
Take a look at Theravance Biopharma Inc’s (TBPH) current performance indicators. Last quarter, stock had a quick ratio of 6.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.93. Likewise, its price to free cash flow for the trailing twelve months is 3.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.23, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach 0.30 in one year’s time.
Technical Analysis of Theravance Biopharma Inc (TBPH)
Looking closely at Theravance Biopharma Inc (NASDAQ: TBPH), its last 5-days average volume was 0.39 million, which is a jump from its year-to-date volume of 0.3 million. As of the previous 9 days, the stock’s Stochastic %D was 85.16%.
During the past 100 days, Theravance Biopharma Inc’s (TBPH) raw stochastic average was set at 97.66%, which indicates a significant increase from 93.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.47 in the past 14 days, which was higher than the 0.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.12, while its 200-day Moving Average is $11.12. However, in the short run, Theravance Biopharma Inc’s stock first resistance to watch stands at $15.55. Second resistance stands at $15.88. The third major resistance level sits at $16.42. If the price goes on to break the first support level at $14.68, it is likely to go to the next support level at $14.13. Should the price break the second support level, the third support level stands at $13.80.
Theravance Biopharma Inc (NASDAQ: TBPH) Key Stats
The company with the Market Capitalisation of 766.50 million has total of 50,361K Shares Outstanding. Its annual sales at the moment are 64,380 K in contrast with the sum of -56,420 K annual income. Company’s last quarter sales were recorded 26,200 K and last quarter income was 54,840 K.
